Los Angeles, CA Clinical Trials Report — June 2026

For patients and healthy volunteers in Los Angeles, CA, June 2026 presents a dynamic landscape of clinical research opportunities, with some trials requiring prompt action due to impending deadlines, and many new studies opening their doors. Across Los Angeles, a robust total of 1,834 clinical trials are currently recruiting participants at 767 research facilities.

Act Now: Trials Closing Soon in Los Angeles

Time is of the essence for those considering participation in clinical research, as a significant number of trials are nearing their enrollment deadlines. A total of 144 clinical trials in Los Angeles are scheduled to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, with 26 of these rapidly concluding studies still actively seeking participants without specific health conditions.

Patients managing specific health conditions also have limited time to join research, with trials focused on various conditions approaching their enrollment cut-off dates. Conditions with trials closing soon include:

• Breast cancer (8 trials)
• Prostate cancer (6 trials)
• Anxiety (4 trials)
• Ovarian cancer (4 trials)
• Pancreatic cancer (4 trials)
• Advanced solid tumor (4 trials)
• Fear (3 trials)
• Type 2 diabetes (3 trials)
• Stroke (3 trials)
• Pain (3 trials)

New Research Opportunities Emerge This Month

June 2026 brings 31 new clinical trials to Los Angeles, a slight decrease from the 32 trials that opened in May 2026. These new studies contribute to the city's vibrant research environment, offering fresh avenues for participation in cutting-edge medical advancements.

Among the new trials, several notable studies from major sponsors and academic institutions are now recruiting. These include significant Phase 3 drug trials and large-scale behavioral interventions:

• AstraZeneca is sponsoring a major Phase 3 study, NCT07662109, "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial aims to enroll 2,000 participants to evaluate the efficacy, safety, and tolerability of a combination therapy for adults with type 2 diabetes mellitus inadequately managed by current treatments.
• Kallyope Inc. has launched two Phase 3 trials focused on migraine treatment. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized, multicenter study targeting 1,800 participants to assess elismetrep's effectiveness and safety compared to placebo. Complementing this, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," seeks 1,000 participants to evaluate the long-term safety and tolerability of intermittent elismetrep use.
• The University of Alabama at Birmingham is sponsoring NCT07671937, "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study." This study, aiming for 2,748 participants, will characterize multidisciplinary tumor board practices and assess the impact of an intervention involving patient-reported evaluations.
• The University of California, Los Angeles is leading NCT07671976, "Applying the Intention-Action Framework to Specialty Referrals." This prospective randomized controlled trial involves 1,600 participants and evaluates an EHR-embedded behavioral intervention designed to reduce low-value specialty referrals in cardiology, pulmonology, and gastroenterology.
• Montefiore Medical Center is sponsoring NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study, with 512 participants, investigates whether offering buprenorphine treatment directly at syringe service programs is more effective for opioid use disorder than traditional referrals.

New trials this month are exploring a range of conditions, with the most frequent being migraine (2 trials), advanced endometrial carcinoma (1 trial), critical illness (1 trial), alcohol consumption (1 trial), and ARDS (1 trial). Drug trials account for the largest share of new studies, with 16 new drug trials, followed by 11 behavioral studies and 9 "OTHER" type studies. Academic institutions like Jonsson Comprehensive Cancer Center (3 trials), University of Southern California (3 trials), and Cedars-Sinai Medical Center (2 trials) are leading many new studies, alongside industry sponsors such as AstraZeneca (2 trials) and Kallyope Inc. (2 trials).

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to research in Los Angeles. Of the 31 new trials launched this month, 7 are actively seeking healthy volunteers. Overall, a total of 184 clinical trials are currently recruiting healthy participants across Los Angeles, providing numerous avenues for those interested in supporting medical research.

Los Angeles' Leading Research Facilities

Los Angeles is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Cedars-Sinai Medical Center (215 trials)
• Children's Hospital Los Angeles (113 trials)
• University of California, Los Angeles (89 trials)
• University of Southern California (81 trials)
• USC / Norris Comprehensive Cancer Center (80 trials)
• University of California Los Angeles (65 trials)
• Cedars Sinai Medical Center (61 trials)
• Los Angeles General Medical Center (60 trials)
• UCLA / Jonsson Comprehensive Cancer Center (58 trials)
• UCLA (50 trials)
• USC Norris Comprehensive Cancer Center (48 trials)

These institutions offer a broad spectrum of research, from pediatric studies at Children's Hospital Los Angeles to diverse medical fields at Cedars-Sinai Medical Center and the various University of California and University of Southern California campuses and cancer centers.

Broadening Your Search: Nearby California Options

While Los Angeles offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within California. Other cities with active trials include San Francisco (17 trials), San Diego (16 trials), Palo Alto (10 trials), La Jolla (9 trials), Stanford (7 trials), Sacramento (6 trials), Duarte (6 trials), and Walnut Creek (6 trials).

Participation in clinical trials in Los Angeles is open to a diverse range of individuals. Of the 31 new trials launched this month, 24 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, 3 are female-only, and 2 are male-only. As Los Angeles continues to be a hub for medical innovation, these diverse opportunities ensure that many can contribute to advancing healthcare.